CIK 0001636282
- Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464312787
- Phone
- +1 617-651-5940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Director sold 80,000 shares at an average $74.40 ($5,952,050)
- 4 Planned sale Chief Financial Officer sold 12,500 shares at $71.37 ($892,125)
- 4 Planned sale Chief Medical Officer sold 78,333 shares at an average $71.50 ($5,600,701)
- 4 Planned sale Chief Executive Officer sold 15,000 shares at an average $71.37 ($1,070,507)
- 4 Planned sale Chief Executive Officer sold 15,000 shares at an average $49.33 ($739,912)
- 4 Planned sale Chief Medical Officer sold 7,958 shares at $50.00 ($397,900)
- 4 Planned sale Chief Financial Officer sold 7,500 shares at an average $49.34 ($370,076)
- 4 Planned sale Chief Financial Officer sold 2,500 shares at an average $40.65 ($101,620)
- 4 Planned sale Chief Executive Officer sold 15,000 shares at an average $42.19 ($632,866)
- 4 Planned sale Chief Executive Officer sold 15,000 shares at an average $32.80 ($492,045)
- 4 Other acquisition Director acquired 63,227 shares (other)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Executive Officer sold 15,000 shares at an average $30.68 ($460,134)
Page 2 of 14 · 271 filings